s'authentifier
version française rss feed
The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells.
Belguise K., Milord S., Galtier F., Moquet-Torcy G., Piechaczyk M., Chalbos D.
Oncogene 31, 47 (2012) 4889-97 - http://www.hal.inserm.fr/inserm-00668852
 (22286759) 
The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells.
Karine Belguise1, Sandrine Milord1, Florence Galtier1, Gabriel Moquet-Torcy2, Marc Piechaczyk2, Dany Chalbos () 1
1 :  IRCM - Institut de recherche en cancérologie de Montpellier
INSERM : U896 – Université Montpellier I – CRLCC Val d'Aurelle - Paul Lamarque
208 rue des Apothicaires F-34298 Montpellier
France
2 :  IGMM - Institut de génétique moléculaire de Montpellier
http://www.igm.cnrs-mop.fr/
CNRS : UMR5535 – Université Montpellier II - Sciences et techniques
1919 Route de Mende 34293 MONTPELLIER CEDEX 5
France
PKCθ pathway stabilises Fra-1
Fra-1 is aberrantly expressed in a large number of cancer cells and tissues, and emerging evidence suggests an important role for this Fos family protein in both oncogenesis and the progression or maintenance of many tumour types. Here, we show that the concentration of Fra-1 is high in invasive oestrogen receptor (ER)-negative (ER-) breast cancer cell lines, regardless of their Ras pathway status. All of the ER- cells express high levels of activated PKCθ, and the inhibition of PKCθ activity using RNA interference or the expression of a dominant-negative mutant results in a dramatic reduction in Fra-1 abundance. Conversely, the ectopic expression of constitutively active PKCθ leads to Fra-1 phosphorylation and accumulation in poorly invasive ER+ cells. This accumulation is due to the stabilisation of the Fra-1 protein through PKCθ signalling, whereas other members of the PKC family are ineffective. Both Ste20-related proline-alanine-rich kinase (SPAK) and ERK1/2, whose activities are upregulated by PKCθ, participate in PKCθ-driven Fra-1 stabilisation. Interestingly, their relative contributions appear to be different depending on the cell line studied. ERK1/2 signalling has a major role in ER- MDA-MB-231 cells, whereas Fra-1 accumulation occurs mainly through SPAK signalling in ER- BT549 cells. Fra-1 mutational analysis shows that the phosphorylation of S265, T223 and T230 is critical for PKCθ-driven Fra-1 stabilisation. Phosphorylation of the protein was confirmed using specific antisera against Fra-1 phosphorylated on T223 or S265. In addition, Fra-1 participates in PKCθ-induced cell invasion and is necessary for PKCθ-induced cell migration. In summary, we identified PKCθ signalling as an important regulator of Fra-1 accumulation in ER- breast cancer cells. Moreover, our results suggest that PKCθ could participate in progression of some breast cancers and could be a new therapeutic target.
Sciences du Vivant/Biochimie, Biologie Moléculaire
Sciences du Vivant/Cancérologie
Anglais
0950-9232

Articles dans des revues avec comité de lecture
10.1038/onc.2011.659
Oncogene (Oncogene)
Publisher Nature Publishing Group: Open Access Hybrid Model Option B
ISSN 0950-9232 (eISSN : 1476-5594)
internationale
22/11/2012
30/01/2012
31
47
4889-97

Breast Neoplasms – Cell Line – Tumor – Cell Movement – Female – Humans – Isoenzymes – MAP Kinase Signaling System – Phosphorylation – Protein Kinase C – Protein Processing – Post-Translational – Protein Stability – Protein-Serine-Threonine Kinases – Proto-Oncogene Proteins c-fos – Receptors – Estrogen
This work was supported by the " Institut National de la Santé et de la Recherche Médicale ", the University of Montpellier 1, the " Ligue Nationale Contre le Cancer-comité de l'Hérault ", the " Association pour la Recherche sur le Cancer " (fellowship to K. Belguise) and the French "Ministère de la Recherche et de l'Enseignement Supérieur" (fellowship to S. Milord). M. Piechaczyk's laboratory was supported as an " Equipe Labellisée " of the " Ligue Nationale Contre le Cancer ".
Liste des fichiers attachés à ce document : 
DOC
PKC-oncogene-07-12.doc(160 KB)
PDF
Figures_061211.pdf(1.6 MB)
PKC-oncogene-07-12.pdf(252.9 KB)
inserm-00668852_edited.pdf(555.4 KB)
XHTML
index.xhtml(73.2 KB)

tous les articles de la base du CCSd...